The FGF7 and Noggin Genes Are Key Targets to Treat Hair Loss

Total Page:16

File Type:pdf, Size:1020Kb

The FGF7 and Noggin Genes Are Key Targets to Treat Hair Loss CosmetiCs Hair Loss D. Schmid, E. Belser, F. Zülli* The FGF7 and Noggin Genes are Key Targets to Treat Hair Loss n Introduction portant role in the hair growth cycle. stop proliferation at the end of the ana- After hair follicles are generated in em- gen phase and undergo apoptosis in the The human hair follicle is a complex struc- bryogenesis, the follicles undergo cycli- catagen phase. The onset of a new growth ture consisting of an outer root sheath, cal growth. A hair growth cycle consists phase and thus the length of the anagen an inner root sheath, the hair shaft, the of three phases: anagen, catagen and phase are defined by the release of bulge and the sebaceous gland. The telogen (Fig. 1). Anagen is the growth growth factors from dermal papilla cells. swollen, bottom part of the hair follicle phase that lasts about three to five years. Adjacent, quiescent keratinocyte prog- is called the hair bulb. There highly pro- Afterwards catagen, the involution phase, enitor cells start to proliferate and to liferative matrix keratinocytes produce follows, lasting a couple of weeks. The generate a new hair follicle. the keratinized hair shaft. The ectoder- cycle terminates with the telogen pha- Hair follicles cycle independently, lea- mal matrix encloses a zone of mesen- se, a resting period of up to 4 months. ding to growing, resting and shedding chymal cells, called the dermal papilla. Dermal papilla cells generate signals that hairs at the same time. The density and This well-vascularized zone transfers nu- regulate the activity of keratinocytes in total number of scalp hairs do not change. trients to the hair bulb and plays an im- the follicular matrix. These keratinocytes The proportion of telogen hair is nor- abstract ur hair is permanently in a after three months’ treatment with bottom of the hair bulb and becau- cyclic process which com- a gel containing 4% anagain™, the se the cyclic process of hair growth oprises a growth phase (ana- anagen/telogen ratio improved is regulated by signals of dermal gen), a transitional phase (catagen) from 4 to 7.2. the result is papilla cells. in most of and a resting period (telogen). stronger, healthier, denser-looking the volunteers, anagain™ was healthy hair is characterized by a hair. in order to study how ana- found to increase several times constant proportion of 85 to 90% gain™ works, the gene expression the expression of fibroblast anagen hair. hair loss happens in plucked hair follicles from 10 vo- growth factor-7 (FgF7), a dermal when the proportion of telogen lunteers was analyzed before and papilla signal instructing hair hair increases, leading to a re- after 14 days’ treatment with germ cells to proliferate and ini- duced amount of anagen hair. a hair balm fluid containing 2% tiate a new hair cycle. and nog- anagain™, a new anti-hair loss in- anagain™. the expression of se- gin, a gene that shortens the telo- gredient based on pea sprouts lected marker genes important in gen phase and initiates a new hair (inci name: pisum sativum sprout hair physiology was analyzed us- growth phase was even more sti- extract, phenoxyethanol, sodium ing the rt-qpcr method on mrna mulated. to summarize: ana- benzoate, aqua) was found in a cli- extracted from pooled hair bulbs. gain™ prevents and stops the hair nical study with 20 volunteers to also dermal papilla cell marker loss process and stimulates hair clearly increase the number of genes were analyzed because plu- growth by modulating the expres- hairs in the anagen phase and to cked hair follicles contained sion of the genes of FgF7 and reduce the amount of telogen hair. the dermal papilla tissue at the noggin. 18 SOFW-Journal | 139 | 9-2013 CoSMETICS HAIR loSS mally 10% to 15% (1). Diffuse hair loss is characterized by a uniform reduction of hair density. Telogen effluvium is a diffuse hair loss during stress with pre- mature development of catagen and tel- ogen follicles and premature termina- tion of anagen follicles. A trichogram analysis shows in this case a significant reduction in the anagen:telogen ratio leading to >25% of telogen hair. Triggers for diffuse hair loss include physiologi- cal or emotional stress, a hormonal im- balance or nutritional deficiencies. Fig. 1 The hair growth cycle comprising the growth phase (anagen), the transitional phase (catagen) and the resting period (telogen) n Materials and Methods Anti-hair loss study with photo- trichogram analysis start, immediately after shaving 1 cm2 treatment with the product and the ex- The study was conducted with 17 women of scalp. Another image was made on traction of hair bulbs was performed on and 3 men, aged between 21 and 37. The day 2. Product application was started a test site at the back of the head. The product, a gel containing 4% AnaGain™, on day 3. Another phototrichogram was product was applied twice a day for 2 was applied to the scalp twice daily for performed at the end of the study. weeks. Before the first product applica- 12 weeks. The selected subjects showed tion and again at the end of the study 20 increased hair loss with ≥ 20% telogen Gene expression analysis in plucked hairs hairs were plucked from the test site and hair for men and ≥ 15% telogen hair for The study was conducted with 10 volun- pooled. The plucked hair bulbs were women and with a hair density of at least teers, 4 women and 6 men, aged between cut to about 1 cm length and stored at 150 hairs/cm2. To perform the phototri- 46 and 60. AnaGain™ was formulated at -80 °C. The expression of selected mar- chogram, an image was made at the 2% into a neutral scalp product. The kers was analyzed using RT-qPCR me- 60487 Frankfurt am Main, Insterburger Strasse 7 Tel.: +49 (0)69 74 74 28 0 - Fax: +49 (0)69 74 74 28 20 e-mail: [email protected] Sanddorn hat‘s in sich SOFW-Journal | 139 | 9-2013 19 CosmetiCs Hair Loss thod on mRNA extracted from the two hair pools. Analysis of gene expression was performed in duplicates (n=2) using a dedicated PCR array containing 32 target genes (including 2 housekeeping genes) selected for their importance in hair physiology. The PCRs were perform- ed with the LightCycler® system (Roche Molecular System Inc.). n Results and Discussion Fig. 2 Typical pictures of a phototrichogram analysis Effect of AnaGain™ on Hair Growth Pea sprouts that were a few days old were used as the raw material to produ- ce the ingredient AnaGain™ (INCI name: Pisum Sativum Sprout Extract, Phenoxy- ethanol, Sodium Benzoate, Aqua), inten- ded for the use as an anti-hair loss in- gredient. AnaGain™, formulated at 4% into a gel base, was tested on twenty, mainly fe- male, subjects. The test product was applied on a defined scalp zone, twice a day, over 3 months. Before and after treatment a pho- totrichogram was performed to analyze hair growth. To perform a phototrichogram, a defined scalp zone is shaved and then photo- graphed. A typical picture is shown in Fig. 2. The number of small dots corresponds to total hair follicles. Two days later, the shaved zone is photographed again in order to verify the amount of hair folli- cles in the growing phase (anagen hair). In Fig. 2, hair follicles in the growing Fig. 3 After three months’ treatment, AnaGain™ at 4% clearly reduced the number phase are marked with a green point. As of telogen hair and increased the number of anagen hair shown in Fig. 3, treatment of the scalp with AnaGain™ clearly reduced the den- sity of telogen hair (- 28.3%) and in- creased the density of anagen hair (+ 7.9%). Consequently, the hair growth coefficient which is defined as the ratio of anagen to telogen hair, increased from 4 to 7.2 (Fig. 4). The slightly en- hanced hair loss at the beginning of the study (about 20% telogen hair) of the subjects could be normalized by a three month treatment with AnaGain™ (about 12% telogen hair at the end of the study). The volunteers were asked to eva- luate the efficacy of the treatment in a questionnaire at the end of the study. 95% of the volunteers noticed a slight to strong reduction in hair loss and a slight to strong improvement of the general hair Fig. 4 Effect of AnaGain™ at 4% on the hair growth coefficient (ratio of anagen condition (Fig. 5). 85% of the volunteers to telogen hair) after application for three months noticed renewed hair growth. 20 SOFW-Journal | 139 | 9-2013 CoSMETICS HAIR loSS physiology were followed. The results showed mainly modulation of the ex- pression of fibroblast growth factor 7 (FGF7) and of noggin (Fig. 6). AnaGain™ was found to strongly activate both genes. The expression of FGF7 was in- creased by 56% and of noggin by 85% on average after two weeks’ treatment. FGF7 was stimulated in 8 and noggin in 7 out of the 10 volunteers. The expres- sion products of the genes FGF7 and noggin, the FGF7 and noggin proteins, are well known signaling compounds, important for the induction of a new hair growth phase. Both proteins are Fig. 5 Evaluation questionnaire shows positive effects of AnaGain™ on hair growth mainly synthesized in dermal papilla cells. The plucked hair follicles used for Effect of AnaGain™ on Gene Expression 2% into a neutral scalp product was ap- the gene expression analysis contained Analyzed in Plucked Hairs plied in the morning and evening over the entire hair bulb enclosing the dermal In order to study the mechanism of the two weeks on 10 subjects.
Recommended publications
  • ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are The
    0031-3998/07/6103-0267 PEDIATRIC RESEARCH Vol. 61, No. 3, 2007 Copyright © 2007 International Pediatric Research Foundation, Inc. Printed in U.S.A. ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are the Predominant FGF Ligands Expressed in Human Fetal Growth Plate Cartilage PAVEL KREJCI, DEBORAH KRAKOW, PERTCHOUI B. MEKIKIAN, AND WILLIAM R. WILCOX Medical Genetics Institute [P.K., D.K., P.B.M., W.R.W.], Cedars-Sinai Medical Center, Los Angeles, California 90048; Department of Obstetrics and Gynecology [D.K.] and Department of Pediatrics [W.R.W.], UCLA School of Medicine, Los Angeles, California 90095 ABSTRACT: Fibroblast growth factors (FGF) regulate bone growth, (G380R) or TD (K650E) mutations (4–6). When expressed at but their expression in human cartilage is unclear. Here, we deter- physiologic levels, FGFR3-G380R required, like its wild-type mined the expression of entire FGF family in human fetal growth counterpart, ligand for activation (7). Similarly, in vitro cul- plate cartilage. Using reverse transcriptase PCR, the transcripts for tivated human TD chondrocytes as well as chondrocytes FGF1, 2, 5, 8–14, 16–19, and 21 were found. However, only FGF1, isolated from Fgfr3-K644M mice had an identical time course 2, 17, and 19 were detectable at the protein level. By immunohisto- of Fgfr3 activation compared with wild-type chondrocytes and chemistry, FGF17 and 19 were uniformly expressed within the showed no receptor activation in the absence of ligand (8,9). growth plate. In contrast, FGF1 was found only in proliferating and hypertrophic chondrocytes whereas FGF2 localized predominantly to Despite the importance of the FGF ligand for activation of the resting and proliferating cartilage.
    [Show full text]
  • FGF Signaling Network in the Gastrointestinal Tract (Review)
    163-168 1/6/06 16:12 Page 163 INTERNATIONAL JOURNAL OF ONCOLOGY 29: 163-168, 2006 163 FGF signaling network in the gastrointestinal tract (Review) MASUKO KATOH1 and MASARU KATOH2 1M&M Medical BioInformatics, Hongo 113-0033; 2Genetics and Cell Biology Section, National Cancer Center Research Institute, Tokyo 104-0045, Japan Received March 29, 2006; Accepted May 2, 2006 Abstract. Fibroblast growth factor (FGF) signals are trans- Contents duced through FGF receptors (FGFRs) and FRS2/FRS3- SHP2 (PTPN11)-GRB2 docking protein complex to SOS- 1. Introduction RAS-RAF-MAPKK-MAPK signaling cascade and GAB1/ 2. FGF family GAB2-PI3K-PDK-AKT/aPKC signaling cascade. The RAS~ 3. Regulation of FGF signaling by WNT MAPK signaling cascade is implicated in cell growth and 4. FGF signaling network in the stomach differentiation, the PI3K~AKT signaling cascade in cell 5. FGF signaling network in the colon survival and cell fate determination, and the PI3K~aPKC 6. Clinical application of FGF signaling cascade in cell polarity control. FGF18, FGF20 and 7. Clinical application of FGF signaling inhibitors SPRY4 are potent targets of the canonical WNT signaling 8. Perspectives pathway in the gastrointestinal tract. SPRY4 is the FGF signaling inhibitor functioning as negative feedback apparatus for the WNT/FGF-dependent epithelial proliferation. 1. Introduction Recombinant FGF7 and FGF20 proteins are applicable for treatment of chemotherapy/radiation-induced mucosal injury, Fibroblast growth factor (FGF) family proteins play key roles while recombinant FGF2 protein and FGF4 expression vector in growth and survival of stem cells during embryogenesis, are applicable for therapeutic angiogenesis. Helicobacter tissues regeneration, and carcinogenesis (1-4).
    [Show full text]
  • The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives
    cancers Review The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives Maria Francesca Santolla and Marcello Maggiolini * Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy; [email protected] * Correspondence: [email protected] or [email protected] Received: 8 September 2020; Accepted: 16 October 2020; Published: 18 October 2020 Simple Summary: The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system represents an emerging therapeutic target in breast cancer. Here, we discussed previous studies dealing with FGFR molecular aberrations, the alterations in the FGF/FGFR signaling across the different subtypes of breast cancer, the functional interplay between the FGF/FGFR axis and important components of the breast microenvironment, the therapeutic usefulness of FGF/FGFR inhibitors for the treatment of breast cancer. Abstract: One of the major challenges in the treatment of breast cancer is the heterogeneous nature of the disease. With multiple subtypes of breast cancer identified, there is an unmet clinical need for the development of therapies particularly for the less tractable subtypes. Several transduction mechanisms are involved in the progression of breast cancer, therefore making the assessment of the molecular landscape that characterizes each patient intricate. Over the last decade, numerous studies have focused on the development of tyrosine kinase inhibitors (TKIs) to target the main pathways dysregulated in breast cancer, however their effectiveness is often limited either by resistance to treatments or the appearance of adverse effects. In this context, the fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system represents an emerging transduction pathway and therapeutic target to be fully investigated among the diverse anti-cancer settings in breast cancer.
    [Show full text]
  • Ep 3217179 A1
    (19) TZZ¥ ___T (11) EP 3 217 179 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 13.09.2017 Bulletin 2017/37 G01N 33/68 (2006.01) (21) Application number: 17167637.2 (22) Date of filing: 02.10.2013 (84) Designated Contracting States: • LIU, Xinjun AL AT BE BG CH CY CZ DE DK EE ES FI FR GB San Diego, CA 92130 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • HAUENSTEIN, Scott PL PT RO RS SE SI SK SM TR San Diego, CA 92130 (US) • KIRKLAND, Richard (30) Priority: 05.10.2012 US 201261710491 P San Diego, CA 92111 (US) 17.05.2013 US 201361824959 P (74) Representative: Krishnan, Sri (62) Document number(s) of the earlier application(s) in Nestec S.A. accordance with Art. 76 EPC: Centre de Recherche Nestlé 13779638.9 / 2 904 405 Vers-chez-les-Blanc Case Postale 44 (71) Applicant: Nestec S.A. 1000 Lausanne 26 (CH) 1800 Vevey (CH) Remarks: (72) Inventors: This application was filed on 21-04-2017 as a • SINGH, Sharat divisional application to the application mentioned Rancho Santa Fe, CA 92127 (US) under INID code 62. (54) METHODS FOR PREDICTING AND MONITORING MUCOSAL HEALING (57) The present invention provides methods for pre- an individual with a disease such as IBD. Information on dicting the likelihood of mucosal healing in an individual mucosal healing status derived from the use of the with a disease such as inflammatory bowel disease present invention can also aid in optimizing therapy (IBD).
    [Show full text]
  • Mechanism of FGF7 Gene Silencing in Regulating Viability, Apoptosis, Invasion of Retinoblastoma Cell Line HXO-Rb44 and Angiogenesis
    European Review for Medical and Pharmacological Sciences 2020; 24: 3538-3547 Mechanism of FGF7 gene silencing in regulating viability, apoptosis, invasion of retinoblastoma cell line HXO-Rb44 and angiogenesis W.-J. CHEN1, C.-X. SUN2, W. LI3 1Department of Orthopedics Surgery, Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei Province, China 2Department of Ophthalmology, Yueyang Huashahengkang Hospital, Yueyang, Hunan Province, China 3Department of Ophthalmology, Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei Province, China Abstract. – OBJECTIVE: To explore the mech- Key Words: anism of fibroblast growth factor 7 (FGF7) gene Gene silencing, Retinoblastoma, Apoptosis, Inva- silencing in regulating viability, apoptosis, inva- sion. sion of retinoblastoma (RB) cell line HXO-Rb44 and angiogenesis. MATERIALS AND METHODS: Human normal retinal vascular endothelial cells ACBRI-181 was set as the normal group. The cultured RB cell lines Introduction HXO-Rb44 were divided into three groups: the blank group (without plasmid transfection), nega- Retinoblastoma (RB) is a common primary tive control group (transfection of FGF7 plasmid), intraocular malignant cancer in children that aris- and the si-FGF7 group (transfection of FGF7 siR- NA plasmid). Quantitative Real Time-Polymerase es mainly in the embryonal nuclear layer of the Chain Reaction and Western blot were used to retina. Retinoblastoma is often accompanied by measure the mRNA and protein expression of strabismus and leukocoria in children1. Early di- B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X agnosis and treatment of RB is the key to improve protein (Bax), vascular endothelial growth fac- eye retention rate.
    [Show full text]
  • FGF7 Is a Functional Niche Signal Required for Stimulation of Adult Liver Progenitor Cells That Support Liver Regeneration
    Downloaded from genesdev.cshlp.org on October 4, 2021 - Published by Cold Spring Harbor Laboratory Press FGF7 is a functional niche signal required for stimulation of adult liver progenitor cells that support liver regeneration Hinako M. Takase,1,5,6 Tohru Itoh,1,5,7 Seitaro Ino,1 Ting Wang,2 Takehiko Koji,3 Shizuo Akira,4 Yasuhiro Takikawa,2 and Atsushi Miyajima1 1Laboratory of Cell Growth and Differentiation, Institute of Molecular and Cellular Biosciences, The University of Tokyo, Tokyo 113-0032, Japan; 2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate 020-8505, Japan; 3Department of Histology and Cell Biology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan; 4Laboratory of Host Defense, World Premier International Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan The liver is a unique organ with a remarkably high potential to regenerate upon injuries. In severely damaged livers where hepatocyte proliferation is impaired, facultative liver progenitor cells (LPCs) proliferate and are assumed to contribute to regeneration. An expansion of LPCs is often observed in patients with various types of liver diseases. However, the underlying mechanism of LPC activation still remains largely unknown. Here we show that a member of the fibroblast growth factor (FGF) family, FGF7, is a critical regulator of LPCs. Its expression was induced concomitantly with LPC response in the liver of mouse models as well as in the serum of patients with acute liver failure. Fgf7-deficient mice exhibited markedly depressed LPC expansion and higher mortality upon toxin-induced hepatic injury. Transgenic expression of FGF7 in vivo led to the induction of cells with characteristics of LPCs and ameliorated hepatic dysfunction.
    [Show full text]
  • Mesenchymal Stem Cells: Mechanisms of Potential Therapeutic Benefi T in ARDS and Sepsis
    Review Mesenchymal stem cells: mechanisms of potential therapeutic benefi t in ARDS and sepsis James Walter, Lorraine B Ware, Michael A Matthay Multipotent mesenchymal stem (stromal) cells (MSCs) have shown promising therapeutic eff ects in preclinical Lancet Respir Med 2014 models of both acute respiratory distress syndrome (ARDS) and sepsis. Although initial research focused on the Published Online ability of MSCs to engraft at sites of tissue injury, increasing evidence suggests that MSCs have their therapeutic October 28, 2014 eff ects through mechanisms unrelated to long-term incorporation into host tissue. One of the most compelling of http://dx.doi.org/10.1016/ S2213-2600(14)70217-6 these pathways is the ability of MSCs to interact with injured tissue through the release of soluble bioactive factors. Departments of Medicine and This Review provides an overview of the general properties of MSCs, and then outlines ways in which the paracrine Anaesthesia, Cardiovascular eff ects of MSCs might reduce lung injury and enhance lung repair in ARDS and sepsis. Finally, we summarise Research Institute, University ongoing challenges in MSC research and identify areas in which the discipline might progress in the coming years. of California, San Francisco, CA, USA (J Walter MD, M A Matthay MD); and Division 12 Introduction lifespan in vivo. Finally, once isolated from host tissue, of Allergy, Pulmonary and Advances in supportive care have markedly improved MSCs can be expanded rapidly ex vivo, which enables Critical Care Medicine, survival for
    [Show full text]
  • Derived Keratinocyte Growth Factor and Epithelial Transforming Growth Factor in Immune- Mediated Crypt Cell Hyperplasia
    Interactions between stromal cell--derived keratinocyte growth factor and epithelial transforming growth factor in immune- mediated crypt cell hyperplasia. M Bajaj-Elliott, … , N C Wathen, T T MacDonald J Clin Invest. 1998;102(8):1473-1480. https://doi.org/10.1172/JCI2792. Research Article Immune reactions in the gut are associated with increased epithelial cell proliferation. Here we have studied the role of keratinocyte growth factor (KGF; FGF7) and transforming growth factor-alpha (TGF-alpha) in the epithelial cell hyperplasia seen in explants of fetal human small intestine after activation of lamina propria T cells with the superantigen Staphylococcus aureus enterotoxin B (SEB). After the addition of SEB to the explants there is a 10-fold increase in KGF mRNA by 72 h of culture. KGF transcripts were abundant in the lamina propria using in situ hybridization and the culture supernatants contained elevated amounts of KGF protein. SEB had no direct effect on KGF mRNA and protein production by cultured lamina propria mesenchymal cells, but both were upregulated by TNF-alpha. Accompanying the increase in KGF there was also an increase in TGF-alpha precursor proteins in the culture supernatants and the phosphorylated form of the EGFR receptor was also detected in the tissue. Increased TGF-alpha precursor proteins were also detected in the supernatants of control explants stimulated with KGF alone. The direct addition of KGF and TGF-alpha enhanced epithelial cell proliferation and antibodies against KGF and TGF-alpha partially inhibited SEB-induced crypt hyperplasia. These results suggest molecular cross-talk between the KGF/KGFR and the TGF-alpha/EGFR in immune-mediated crypt cell hyperplasia.
    [Show full text]
  • The MAPKERK-1,2 Pathway Integrates Distinct and Antagonistic Signals from TGF Alpha and FGF7 in Morphogenesis of Mouse Mammary Epithelium
    Lawrence Berkeley National Laboratory Lawrence Berkeley National Laboratory Title The MAPKERK-1,2 pathway integrates distinct and antagonistic signals from TGF alpha and FGF7 in morphogenesis of mouse mammary epithelium Permalink https://escholarship.org/uc/item/7075z967 Author Fata, Jimmie E Publication Date 2007-03-16 DOI 10.1016/j.ydbio.2007.03.013 Peer reviewed eScholarship.org Powered by the California Digital Library University of California The MAPKERK-1,2 pathway integrates distinct and antagonistic signals from TGFα and FGF7 in morphogenesis of mouse mammary epithelium Jimmie E. Fata a* Hidetoshi Mori a, Andrew J. Ewald b, Hui Zhang a, Evelyn Yao a, Zena Werb b, Mina J. Bissell a* a Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA b Department of Anatomy, University of California, San Francisco, CA 94143, USA *Corresponding Authors: Jimmie Fata Life Science Division, Lawrence Berkeley National Laboratory One Cyclotron Road, Berkeley, CA 94720, USA e-mail: [email protected] Mina Bissell Life Science Division, Lawrence Berkeley National Laboratory One Cyclotron Road, MS 977R225A, Berkeley, CA 94720, USA e-mail: [email protected] Tel: +1 510 486 4365 Fax: +1 510 486 5586 LBNL/DOE funding & contract number: DE-AC02-05CH11231 Abstract Transforming growth factor-α (TGFα) and fibroblast growth factor-7 (FGF7) exhibit distinct expression patterns in the mammary gland. Both factors signal through mitogen- activated kinase/extracellular regulated kinase-1,2 (MAPKERK1,2); however, their unique and/or combined contributions to mammary morphogenesis have not been examined. In ex vivo mammary explants, we show that a sustained activation of MAPKERK1,2 for 1 h, induced by TGFα, was necessary and sufficient to initiate branching morphogenesis, whereas a transient activation (15 min) of MAPKERK1,2, induced by FGF7, led to growth without branching.
    [Show full text]
  • Increased Keratinocyte Proliferation by JUN-Dependent Expression of PTN and SDF-1 in Fibroblasts
    Research Article 1981 Increased keratinocyte proliferation by JUN-dependent expression of PTN and SDF-1 in fibroblasts Lore Florin1, Nicole Maas-Szabowski2, Sabine Werner3, Axel Szabowski1 and Peter Angel1,* 1Division of Signal Transduction and Growth Control, and 2Division of Differentiation and Carcinogenesis, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany 3Institute of Cell Biology, ETH Zürich, Hoenggerberg, 8093 Zürich, Switzerland *Author for correspondence (e-mail: [email protected]) Accepted 3 February 2005 Journal of Cell Science 118, 1981-1989 Published by The Company of Biologists 2005 doi:10.1242/jcs.02303 Summary In skin, fibroblasts of the connective tissue play a decisive on primary human keratinocytes. Moreover, SDF-1- role in epidermal homeostasis and repair by contributing induced keratinocyte proliferation could be specifically to the regulation of keratinocyte proliferation and inhibited by neutralizing antibodies against SDF-1 or its differentiation. The AP-1 transcription factor subunit JUN receptor, CXCR4. Consistent with its role in promoting plays a crucial role in this mesenchymal-epithelial interplay keratinocyte growth, PTN was upregulated during by regulating the expression of two critical paracrine- cutaneous wound healing in vivo. Interestingly, co- acting cytokines, keratinocyte growth factor (KGF) and cultivation with keratinocytes stimulated PTN expression granulocyte-macrophage colony-stimulating factor (GM- but repressed SDF-1 production in fibroblasts, CSF). We have performed gene expression profiling of wild- demonstrating the complexity of the paracrine regulatory type and Jun–/– mouse embryonic fibroblasts to identify cytokine networks that control skin homeostasis and additional players involved in this complex network, and regeneration. have found pleiotrophin (PTN) and the stromal cell-derived factor 1 (SDF-1) as novel JUN-regulated factors.
    [Show full text]
  • Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis
    cells Review Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis Jinglin Zhang 1,2,3, Patrick M. K. Tang 1, Yuhang Zhou 1,2,3, Alfred S. L. Cheng 4, Jun Yu 2,5, Wei Kang 1,2,3,* and Ka Fai To 1,2,3,* 1 Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; [email protected] (J.Z.); [email protected] (P.M.K.T.); [email protected] (Y.Z.) 2 Institute of Digestive Disease, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China; [email protected] 3 Li Ka Shing Institute of Health Science, Sir Y.K. Pao Cancer Center, The Chinese University of Hong Kong, Hong Kong, China 4 School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China; [email protected] 5 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China * Correspondence: [email protected] (W.K.); [email protected] (K.F.T.); Tel.: +(852)-3505-1505 (W.K.); Fax: +(852)-2649-7286 (W.K.) Received: 23 May 2019; Accepted: 24 June 2019; Published: 25 June 2019 Abstract: Gastric cancer (GC) is one of the most wide-spread malignancies in the world. The oncogenic role of signaling of fibroblast growing factors (FGFs) and their receptors (FGFRs) in gastric tumorigenesis has been gradually elucidated by recent studies. The expression pattern and clinical correlations of FGF and FGFR family members have been comprehensively delineated.
    [Show full text]
  • Review Peptide Gene Expression in Gastrointestinal Mucosal
    286 Gut 2000;46:286–292 Review Gut: first published as 10.1136/gut.46.2.286 on 1 February 2000. Downloaded from Peptide gene expression in gastrointestinal mucosal ulceration: ordered sequence or redundancy? Summary repair by stimulating the migration of surviving cells from Many genes, some encoding peptides, are upregulated after the edge of the damaged region over the denuded area, a mucosal damage in the gastrointestinal mucosa: we have process known as epithelial restitution. Exogenous looked for an ordered sequence in the expression of genes TFF2/SP increases cell migration in in vitro models of cell such as c-fos,c-jun, egr-1, Sp-1, epidermal growth factor, wounding34and also acts as a cytoprotective agent in rats transforming growth factors á and â, trefoil peptides, epi- treated with indomethacin. Thus TFF2/SP has been dermal growth factor receptor, hepatocyte growth factor, proposed as a rapid response peptide.5 c-met, fibroblast growth factor, platelet derived growth fac- Epidermal growth factor (EGF) is an 53 amino acid tor, and vascular endothelial growth factor. All of these peptide found in the salivary glands and the duodenal gene products play an important reparative role, assisting Brunner’s glands. It is one of the most extensively studied appropriate healing of the damaged mucosa. There does peptides in healing of gastric mucosal lesions,6–9 but its indeed seem to be a temporal sequence in this gene exact function in human physiology is not yet fully defined. expression, but there is a certain degree of redundancy EGF is a potent stimulant of growth and repair when within the system, both in terms of receptor binding and infused systemically, inhibits gastric acid secretion, and has the function of the gene products.
    [Show full text]